agilon health Inc
$ 0.39
-9.15%
24 Feb - close price
- Market Cap 163,345,000 USD
- Current Price $ 0.39
- High / Low $ 0.45 / 0.39
- Stock P/E N/A
- Book Value 0.74
- EPS -0.78
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.73 %
- 52 Week High 6.08
- 52 Week Low 0.34
About
agilon health, inc. The company is headquartered in Long Beach, California.
Analyst Target Price
$0.99
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-04 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-05-09 | 2023-03-01 |
| Reported EPS | -0.27 | -0.25 | -0.0084 | -0.25 | -0.29 | -0.07 | -0.01 | -0.41 | -0.08 | -0.04 | 0.04 | -0.14 |
| Estimated EPS | -0.15 | -0.11 | 0.0114 | -0.128 | -0.11 | -0.08 | -0.01 | -0.3 | -0.06 | -0.03 | 0.02 | -0.09 |
| Surprise | -0.12 | -0.14 | -0.0198 | -0.122 | -0.18 | 0.01 | 0 | -0.11 | -0.02 | -0.01 | 0.02 | -0.05 |
| Surprise Percentage | -80% | -127.2727% | -173.6842% | -95.3125% | -163.6364% | 12.5% | 0% | -36.6667% | -33.3333% | -33.3333% | 100% | -55.5556% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGL
2026-02-24 14:53:48
The Portnoy Law Firm has announced a class action lawsuit against agilon health, inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025. The lawsuit alleges that agilon health issued recklessly optimistic guidance for 2025 and overstated the positive financial impact of strategic actions, leading to a significant stock price drop after disappointing financial results and the CEO's departure. Investors have until March 2, 2026, to file a lead plaintiff motion.
2026-02-24 13:53:48
The Gross Law Firm is reminding shareholders of agilon health, inc. (NYSE: AGL) about an upcoming lead plaintiff deadline of March 2, 2026. The lawsuit alleges that agilon health issued materially false and misleading statements regarding its 2025 guidance and the financial impact of strategic actions. Shareholders who purchased AGL shares between February 26, 2025, and August 4, 2025, are encouraged to contact the firm.
2026-02-24 03:52:17
Agilon Health (AGL) is set to report earnings this Wednesday after the bell. The company previously missed revenue and EPS estimates, and analysts expect a 3.9% year-on-year revenue decline for the upcoming quarter. Its stock has significantly underperformed peers and the broader outpatient & specialty care segment, with analysts setting a price target well above its current trading price.
2026-02-23 21:10:52
Levi & Korsinsky, LLP is reminding investors of agilon health, inc. (NYSE: AGL) about a pending class action securities lawsuit. The lawsuit alleges that defendants made false statements and concealed information regarding their 2025 guidance and the financial impact of strategic actions. Investors who suffered losses between February 26, 2025, and August 4, 2025, have until March 2, 2026, to request to be appointed as lead plaintiff.
2026-02-23 19:16:58
A lawsuit deadline is approaching on March 2, 2026, for investors who purchased shares of agilon health, inc. (NYSE: AGL) between February 26, 2025, and August 4, 2025. The lawsuit alleges that the company made false and misleading statements regarding its 2025 guidance and the financial impact of strategic actions, with shares declining significantly after the withdrawal of earnings guidance and CEO's departure in August 2025. Investors are encouraged to contact the Shareholders Foundation for options regarding the litigation.
2026-02-23 16:52:17
Several healthcare and medical technology stocks including iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics traded down in the morning session. This decline followed the Trump administration's announcement of new global tariffs, reigniting trade policy uncertainty despite a recent Supreme Court ruling against such duties. The administration invoked the Trade Act of 1974 to impose a 15% global tariff for up to 150 days, creating uncertainty for companies reliant on international supply chains.
